Skip to Content
Merck
  • Intranasal in situ gel loaded with saquinavir mesylate nanosized microemulsion: preparation, characterization, and in vivo evaluation.

Intranasal in situ gel loaded with saquinavir mesylate nanosized microemulsion: preparation, characterization, and in vivo evaluation.

International journal of pharmaceutics (2014-09-03)
Khaled Mohamed Hosny, Ali Habiballah Hassan
ABSTRACT

Saquinavir mesylate (SM) is a protease inhibitor with activity against human immunodeficiency virus type 1 (HIV-1) and is available in tablet form, which has three major problems. First, the drug undergoes extensive first pass metabolism. Second, the drug has a poor aqueous solubility. And third, it has low GIT permeability and absorption. These constrains lead to decrease oral bioavailability (4% only) and administration of large doses which increase the incidence of occurrence of the side effects. The aim of this research was to utilize nanotechnology to formulate (SM) into a nasal in situ nanosized microemulsion gel (NEG) to provide a solution for the previously mentioned problems. The solubility of (SM) in various oils, surfactants, and cosurfactants was estimated. Pseudo-ternary phase diagrams were developed and various nanosized microemulsion (NE) were prepared, and subjected to characterization, stability study, and droplet size measurements. Gellan gum was used as an in situ gelling agent. The gel strength, critical ionic concentration, gelation characteristics, in vitro release, and ex vivo nasal permeation were determined. The pharmacokinetic study was carried out in rabbits. Stable NEs were successfully developed with a droplet size range of 25-61 nm. A NEG composed of 17.5% Labrafac PG, 33% Labrasol, and 11% Transcutol HP successfully provided the maximum in vitro and ex vivo permeation, and enhanced the bioavailability in the rabbits by 12-fold when compared with the marketed tablets. It can be concluded that the nasal NEG is a promising novel formula for (SM) that has higher nasal tissue permeability and enhanced systemic bioavailability.

MATERIALS
Product Number
Brand
Product Description

Supelco
Propylene glycol, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Isopropyl myristate, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Triacetin, United States Pharmacopeia (USP) Reference Standard
USP
Dehydrated Alcohol, United States Pharmacopeia (USP) Reference Standard
Supelco
Ethanol solution, certified reference material, 2000 μg/mL in methanol
Supelco
Linoleic acid, analytical standard
Sigma-Aldrich
Triacetin, 99%
Sigma-Aldrich
Linoleic acid, technical, 58-74% (GC)
Sigma-Aldrich
Propylene Glycol, meets USP testing specifications
Sigma-Aldrich
Isopropyl myristate, ≥90% (GC)
USP
Propylene glycol, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Linoleic acid, liquid, BioReagent, suitable for cell culture
Sigma-Aldrich
Propylene glycol, ≥99.5% (GC), FCC, FG
Sigma-Aldrich
Triacetin, 99%, FCC, FG
Sigma-Aldrich
Isopropyl myristate, ≥98%
Sigma-Aldrich
Isopropyl myristate, 98%
Sigma-Aldrich
Isopropyl alcohol, ≥99.7%, FCC, FG
Sigma-Aldrich
Saquinavir mesylate, ≥98% (HPLC), powder
USP
Isopropyl myristate, United States Pharmacopeia (USP) Reference Standard
Supelco
Dehydrated Alcohol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Linoleic acid, ≥99%
Supelco
Triacetin, analytical standard
Propylene glycol, European Pharmacopoeia (EP) Reference Standard
Supelco
Triacetin, Pharmaceutical Secondary Standard; Certified Reference Material
Saquinavir for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Ethanol, tested according to Ph. Eur.
Sigma-Aldrich
1,2-Propanediol, tested according to Ph. Eur.
Sigma-Aldrich
Ethyl alcohol, Pure, 190 proof, ACS spectrophotometric grade, 95.0%
Supelco
1,2-Propanediol, analytical standard
Sigma-Aldrich
2-Propanol, anhydrous, 99.5%